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Abstract The standard treatment of early-stage Hodgkin
lymphoma (ESHL) as recommended by most national guide-
lines is combined modality treatment (CMT) that includes a
short course ABVD followed by a small field of low dose
radiotherapy (RT). Recently a trend to treat patients with more
chemotherapy alone has been promoted by some claiming that
chemotherapy alone is good enough, and the overall survival
is similar. These arguments need to be carefully examined,
and the risk of more chemotherapy upfront and salvage con-
sidered. The suggestion that interim PETwill identify patients
that can have similar results with chemotherapy alone has
recently been questioned by the results of both European
and UK studies. It is the subject of this critical review.
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Introduction
Treating highly curable early-stage Hodgkin lymphoma
(ESHL) patients with chemotherapy alone has recently gath-
ered more steam in North America. Yet, omission of radiother-
apy (RT) is not considered a standard treatment for ESHL in
Europe [1••] or in the UK [2••] Since it is almost guaranteed to
result in worse disease control compared to combined modality
therapy [3]. Notwithstanding, US national statistics indicate that
an increasing number of patients with early HL are not receiv-
ing combined modality therapy [4••]. The recognition that
combined modality is the tried and true standard treatment is
clearly spelled out in recent updates of several national guide-
lines (NCCN, UK, and ESMO). Some have caveats concerning
treatment with chemotherapy alone or consider it still experi-
mental [1••, 2••, 5]. The increasingly popular trend to treat HL
with chemotherapy alone is worrisome for several reasons,
including the possibility that we may see, for the first time in
decades, as the data indirectly suggest, a reversal of the im-
provement in outcome of ESHL patients.
In this article, I will critically analyze data from recent
prospective randomized studies and refute arguments made
in support of omitting RT, often while substituting it with
more chemotherapy.
US data indicate a decrease in the use of RT for ESHL
and worse OS for patients treated with chemotherapy
alone
Recent studies analyzed information on ESHL patients from
two large US databases. Koshi et al., analyzed the Surveil-
lance, Epidemiology, and End Results (SEER) database [4••].
They identified 12,247 ESHL patients diagnosed between
1988-2006 (median follow-up 4.9 years) and showed that
while during the years 1988-1991 63 % of patients received
RT as part of their initial treatment, in 2004-2006 only 44 %
received RT, (p<0.001). The 5-year OS for ESHL that did not
receive RTwas 76 %, significantly inferior when compared to
those who have received RT obtaining a 5-year OS of 87 %
(p<0.001). The hazard ratio adjusted for other variables in the
regression model showed that patients who did not receive RT
(HR – 1.72, 95 % CI – 1.72–2.02) was associated with
significantly worse survival when compared to patients who
received RT. Interestingly, the study showed that the actuarial
rate of developing a second malignancy at 15 years was
14.6 % with RT vs 15.0 % without RT. Similarly, a recent,
yet unpublished study by Parikh et al. (to be reported in
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ASTRO September 2014), the National Cancer Data Base
(NCDB) was used to identify over 40,000 patients with ESHL
frommore than 1,500 sites across the US. It has shown similar
results to the SEER data. Namely, a decrease in the use of RT
in ESHL over the last decade, and unfortunately, a highly
statistically significant inferior overall survival for the group
treated with chemotherapy alone compared to those treated
with combined modality. This effect on OS was independent
of other prognostic factors in a multivariate analysis.
The tangled relationship between freedom from treatment
failure and overall survival in HL
Historically, even the most important randomized studies that
established principles of treatingHL in different eras were judged
primarily on the capacity of the chosen arm to obtain a signifi-
cantly better freedom from treatment failure without undue tox-
icity. In almost all studies, due to salvage options or a small
number of mortality events, OS remained without a demonstrat-
ed advantage to the chosen, better disease controlling arm. A few
of many examples in ESHL are studies of extended-field RT
(EFRT) alone versus involved-field RT (IFRT) alone [6], STLI
vs. AV+STLI (SWOG 9133/CALGB 9391) [7], STLI vs.
ABVDx2+STLI (GHSG HD7) [8], and EBVPX6+IFRT vs
STLI (EORTC H7F) [9]. There are many more; and, indeed,
showing OS advantage in HL randomized studies is a rarity.
There are several reasons for reporting the “same” OS in
spite of better freedom from treatment failure:
1. Effective salvage
Patients who have failed their primary treatment may
be salvaged with high dose chemoradiotherapy and stem
cell transplantation. The potential devastating effects of
this intervention will be discussed later.
2. Long survival with active disease
Many patients can survive with active disease for
several years with temporizing treatments like single
agent vinblastine or palliative RT. A death event may take
many years to occur.
3. Death from other causes.
Overall survival captures death from any cause, and the
more appropriate parameter to look at should be cause
specific survival (CSS) that includes death from disease,
death from complications of salvage, and death from
complications related to treatment such as death from
leukemia, other lymphomas or second solid tumors in
the radiation field (related often to chemotherapy, radio-
therapy or both), heart failure and /or coronary heart
disease (chemotherapy and/or RT). Obviously, deaths
fromAlzheimer’s disease, suicide or drowning as counted
on the combined modality-arm in HD 6 may be mislead-
ing (see below) [10••].
To reach a statistical relevance in a noninferiority study and
avoid a type II statistical error in analyzing OS or even CSS,
the study should have a sufficient number of mortality events.
Fortunately, this is quite rare in early-stage HL and practically
all studies in the modern era have not had adequate death
events to reach a statistical difference. Furthermore, most
studies have been reported after a median of 3-7 years and
collaborative group studies typically lack funding to maintain
an accurate long-term follow-up and determine cause of death
even when they are revisited later.
In order to bypass some of the obstacles of limited statis-
tical power of individual randomized trials, the Cochrane
group analyzed all randomized controlled trials (RCT) com-
paring chemotherapy alone to combined modality therapy in
early-stage HL.[3] Five RCTs involving 1,245 patients were
included. The HR was 0.41 (95 % confidence interval (CI)
0.25 to 0.66) for tumor control and 0.40 (95%CI 0.27 to 0.61)
for OS for patients receiving CMTcompared to chemotherapy
alone. Complete response rates were similar between treat-
ment groups. In sensitivity analyses another six trials were
included that did not fulfill the strict inclusion criteria of the
Cochrane group protocol but were considered relevant to the
topic. These trials underlined the results of the main analysis.
The Cochrane group concluded that adding radiotherapy to
chemotherapy improves tumor control and overall survival in
patients with early-stage Hodgkin lymphoma.
The puzzling results of the Canadian HD6 trial
In synopsis, this is a trial that randomized RT alone, ABVD
alone, and ABVD followed by extended (and outdated) field
RT in favorable and less favorable (but without bulk or with B
symptoms) early-stage HL patients [10••]. The study showed a
significantly better disease control using combined modality
using two cycles of ABVD followed by the long abandoned
subtotal lymphoid (spleen included) RT field (STLI) compared
to the group that received double and often triple the ABVD
dose alone (HR=3.2; p=0.006). Yet, surprisingly, more mor-
tality events (23 patients) occurred in the less favorable group
that received ABVD x2+STLI than in the ABVD alone group
(11 patients) resulting in a better overall survival (p=0.04).
Although this radical RT was abandoned more than two de-
cades ago, several opinion leaders argued that RT should be
eliminated regardless of the advantageous disease control and
in spite of the fact that modern RT uses a very small field that
includes only the involved site and lower doses. Interestingly,
the favorable patients that received STLI alone in HD6 had no
reported long-term mortality and minimal morbidity.
HD6 also serves as an excellent example how a small
number of events, unrelated causes of death, and incomplete
analysis of morbidity may distort the results, conclusion, and
interpretation (Yahalom J: Favorable Early-stage Hodgkin
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Lymphoma and HD.6: The take and the don’t take home
messages. ASCO POST January 15, 2012, Volume 3, Issue
2 and Engert A; Radiotherapy in early-stage Hodgkin
lymphoma, ASCO POST June 15, 2012, Volume 3, Issue 9).
Briefly, one of the caveats is that all mortality events (5) titled
“others” have peculiarly occurred only in the ABVD/STLI
cohort. They included Alzheimer’s disease, accidental drown-
ing, and suicide. In addition, three deaths “related to infection”
were again noted only in the ABVD/STLI arm. Perhaps these
deaths were related to unnecessary irradiation of the spleen in
STLI; but in practice, it is extremely rare to see lethal infec-
tions related to radiation of HL. Remove even only the “other”
deaths from the analysis and the OS in HD 6 is with no
difference in survival between the arms, showing only better
tumor control with the combined modality arm. Other issues
of concern for HD6 are detailed in the references cited above.
The Unfulfilled Promise of Interim PDG-PET Scanning
With the hope that negative FDG-PETafter two cycles or three
cycles of ABVD will identify a group of patients that will
achieve only minimally inferior freedom from treatment failure
(FFTF)with chemotherapy alone, prospective randomized non-
inferiority studies were designed. A consortium of three collab-
orative groups EORTC, GELA, and IIL designed the H10
favorable (F) and unfavorable (U) studies [11] in the UK. The
NCRI lymphoma group designed the RAPID study [12••].
The H10F and H10U were designed as noninferiority stud-
ies that allowed up to 10 % difference in FFTF between the
randomized arms to be considered acceptable, namely showing
that omitting RT is acceptable. Only patients that achieved a
negative PET status after two cycles of ABVD could be ran-
domized to either an additional cycle of ABVD followed by
involved site RT (ISRT) - the “standard” treatment - for the
favorable patients (H10F), or to the experimental treatment that
replaced ISRT with additional cycle of ABVD (total of four).
For the unfavorable ESHL patients who were PET(2)-negative,
the “standard” arm consisted of a total of four cycles of ABVD
followed by ISRT. The experimental arm replaced ISRT with
two additional cycles of ABVD (total of six).
Surprisingly, due to an unexpected number of events (i.e.,
relapses) occurring before the H10 studies finished their
planned accrual; an interim analysis was mandated by the
Internal Data Monitoring Committee of the study. At that
time, 1,137 were studied and 34 events occurred in the nega-
tive PET arms. The investigators decided to terminate the no-
RT arms and mandated that all patients since the interim data
analysis will receive only standard arm that included RT [11].
The reason was an excessive number of failures on the no-RT
arms of both the H10F and H10U. Testing for futility in this
noninferiority trial showed that noninferiority of the arms
(even if allowing for 10 % difference for negative PET
patients) could not be achieved. After two cycles of ABVD,
85.8 % in H10F had a negative PET. On the combined
modality of H10F, there was only one event, but nine events
with chemotherapy alone. On H10U 74.8 % had an early
negative PET with seven events on the combined modality
arm and 16 events with more chemotherapy alone [11].
The UK RAPID trial included ESHL patients without B-
symptoms or mediastinal disease. There were 420 patients
who were negative after three cycles of ABVD. They were
randomized to receive 30Gy of involved field RTor no further
treatment [12••]. RAPIDwas also designed as a noninferiority
trial and the bar was set at 7 % difference between the arms.
The results are conflicting and depend on the parameters for
analysis. If patients are analyzed according to the initial ran-
domization, but not according to the real treatment received,
there was no statistically significant difference between the
arms. But since a substantial number of patients (26 of 211) on
the RT arm, have never received RT, including five patients
who died and one who developed pneumonia shortly after
ABVD have not received any RT, but were scored as RT arm
events. Appropriately, an “as treated” analysis was performed
(but not reported in the meeting abstract). With this more
realistic analysis, the 3-year PFS was 97 % for the combined
modality arm compared to only 90.7 % with chemotherapy
alone (HR=2.39, [13], p=0.03). Thus, in this study, like H10F
and H10U, omitting RT even for negative PET led to an
inferior disease control. Obviously, it is too early for mean-
ingful survival comparisons. Another important caveat in the
interpretation of the RAPID study on the relative prediction of
a “negative” PET is that, in this strictly monitored effort of the
RAPID team, only high quality imaging data were allowed,
and those have been analyzed by only two experts at one
central review center using a conservative definition of PET
negativity [14]. Not necessarily the kind of PET imaging and
analysis that is coming to an imaging facility near you.
Omitting RTequals receiving more chemotherapy, higher
need for salvage, and potentially inferior quality of life
When ABVD alone is offered as an alternative to ABVD+RT,
it normally means that the number of ABVD cycles and, thus,
total dose of each agent will be doubled or tripled [10••]. This
was the case in the HD6 trial and in the H10F or H10U studies.
At the same time, the German Hodgkin study group in their
prospectively randomized trial of HD10 showed that only two
cycles of ABVD followed by 20 Gy IFRT in favorable ESHL
sufficed to achieve excellent FFTF and OS that was similar to
the previous standard of ABVD X4 and IFRT of 30 Gy [15••].
Subjecting 100 % of patients to more ABVD may be risky
and unnecessary. ABVD alone (with no RT) was shown to be
associated with significantly more deaths from myocardial
infarction [13] as well as under reported but clinically
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significant bleomycin induced lung injury [16]. As suggested
by the RAPID study toxic death events after only ABVD, the
risk may be particularly high in elderly patients [17].
Mental and psychological long-term complications of che-
motherapy have not been well studied, but have been the
subject of concern for breast patients who received adjuvant
chemotherapy and discussed first in patient chat rooms and
survivors groups under the title “chemo head”. Only recently,
prospective functional MRI studies documented that changes
in brain activity may underlie chemotherapy induced cogni-
tive complaints in early-stage breast cancer patients receiving
adjuvant chemotherapy [18••]. This is a new concern for our
young and old patients exposed to more courses of chemo-
therapy as initial treatment and in salvage when RT is omitted.
It should be explored further.
Thus, it is likely that 100 % of the patients that will be
advised against RTwill receive more ABVD than in the “2 by
2” approach following the GHSG HD 10 program of only
ABVD X2 and 20 Gy IFRT that is recommended as the
standard treatment for favorable patients [15••]. Unfavorable
patients will receive of ABVD X4 and IFRT of 30 Gy proved
highly effective by the GHSG HD 11 rather than ABVD X6
and had a higher risk of failure [19••].
Chemotherapy alone program will also fail approximately
10 % more favorable patients when compared to a combined
modality program, and even a higher fraction of unfavorable
patients may fail without RT particularly if with bulky
disease.
Most of these patients will require salvage with regimens
like ifosphamide, carboplatinum, and etoposide (ICE),
brentuximab vedotin, larger fields, and higher dose of RT to
the refractory/relapsing sites followed by high dose chemo-
therapy and autologous stem cell transplantation. Although
salvage is quite effective, its potential conern is for immediate
and long-term toxicity being high. The emotional trauma
and mental price for these unfortunate (but mostly avoid-
able or more) 10 % patients is hard to quantify. Many will
lose their fertility and will disrupt their young life plans of
studies and family building. Even if there is only 10 %
risk, is omitting RT justified?
Adding RTwas blamed in the past as a cause of long-term
morbidity. Most of the data come from the era when RT was
used as a single modality, and, at that time, it was the best
curative option if given in maximal dose (over 40 Gy) and
covering all lymph nodes sites from the top of the neck to the
groin, included the spleen and was called, “radical radiother-
apy” or total lymphoid irradiation. Many normal organs were
indiscriminately irradiated with this ancient technique, it in-
cluded the breasts, lungs and heart. This has long been aban-
doned (with the exception of its use in the Canadian HD6
study). The smaller fields used safely in GHSG HD10 and
HD11 and the even smaller involved node RT (INRT) prac-
ticed in the EORTC/GELA/IIL H10F and H10U reassure us
of their efficacy [20]. The modern guidelines published by the
International Lymphoma Radiation Oncology Group
(ILROG) detail the new approach of smaller Involved-Site
RT (ISRT) that can be simply implemented by radiation
oncologists [21••].
To reduce the scare from RT that has flourished over
the last couple of decades, one should recognize that when
the breast is not exposed to radiation (as is possible today
in most patients), the risk of breast cancer is not elevated
[22]. Even those young patients treated years ago and who
had breast exposure are now detected very early with the
use of breast MRI combined with mammography. In a
recent prospective imaging trial, almost all breast cancers
were detected as in-situ lesions or less than 1 cm in size
and are fully curable [23].
The other scare issue was the slightly higher risk of RT-
related coronary heart disease. Interestingly, some studies
showed that the increased risk is mostly detected in patients
with other cardiac risk factors (blood pressure, hyperlipid-
emia, smoking, and diabetes) and rarely is an issue in a cardiac
healthy patient [24]. Today, we proactively monitor other risk
factors, prescribe statins and reduce other risk factors. The
awareness of this relatively minor risk in follow-up provides
an added benefit to HL patients.
What to do?
ESHL patients today should benefit from a well established
effective and safe mini-ABVD and reduced dose mini-field
RT using simple but modern RT technology and concepts as
established byGHSGHD 10 and 11. I am concerned about the
100 % of patients that are likely to receive more ABVD
instead of mini-RT and still be at least at a 10 % risk of failure
and need for salvage high dose therapy.
The interim PET studies confirmed that even negative PET
patients are more likely to fail without RT, yet this group may
be smaller.
The 2014 UK guidelines addressed the exceptional option
of chemotherapy alone properly by recommending that if
chemotherapy alone is considered, the patient should also
have a discussion with a radiation oncologist to hear about
the pros and cons of RT in her/his particular case [2••] Unfor-
tunately, these referrals rarely happen in North America and
many radiation oncologists meet the patients only at the time
of chemotherapy failure. There are individual cases that will
benefit from the chemotherapy alone approach and that could
be determined by radiation oncologists who can identify the
young females who may require RT to a site where breast
tissue cannot be spared from RT. This is how a lymphoma
team should approach an individually tailored curative treat-
ment in 2014. Generalizations, dogmas, and scare are the
ways of the past.
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